133 related articles for article (PubMed ID: 17173064)
1. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Fan Y; Gélinas C
Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
[TBL] [Abstract][Full Text] [Related]
2. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
3. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
[TBL] [Abstract][Full Text] [Related]
4. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
5. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
6. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
Mosialos G; Gilmore TD
Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
[TBL] [Abstract][Full Text] [Related]
7. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
Epinat JC; Dvorin EL; Gilmore TD
Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
[TBL] [Abstract][Full Text] [Related]
8. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
Nehyba J; Hrdlicková R; Bose HR
Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
[TBL] [Abstract][Full Text] [Related]
9. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
Gilmore TD
Oncogene; 1999 Nov; 18(49):6925-37. PubMed ID: 10602467
[TBL] [Abstract][Full Text] [Related]
10. CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.
Dutta J; Fan G; Gélinas C
J Virol; 2008 Nov; 82(21):10792-802. PubMed ID: 18753212
[TBL] [Abstract][Full Text] [Related]
11. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
[TBL] [Abstract][Full Text] [Related]
12. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation.
Zurovec M; Petrenko O; Roll R; Enrietto PJ
Oncogene; 1998 Jun; 16(24):3133-42. PubMed ID: 9671392
[TBL] [Abstract][Full Text] [Related]
13. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
Carrasco D; Rizzo CA; Dorfman K; Bravo R
EMBO J; 1996 Jul; 15(14):3640-50. PubMed ID: 8670867
[TBL] [Abstract][Full Text] [Related]
14. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
Majid SM; Liss AS; You M; Bose HR
Oncogene; 2006 Feb; 25(5):756-68. PubMed ID: 16186799
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
Morrison LE; Boehmelt G; Enrietto PJ
Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
[TBL] [Abstract][Full Text] [Related]
16. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2003 Oct; 22(44):6928-36. PubMed ID: 14534540
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel.
Fujii M; Minamino T; Nomura M; Miyamoto KI; Tanaka J; Seiki M
Oncogene; 1996 May; 12(10):2193-202. PubMed ID: 8668346
[TBL] [Abstract][Full Text] [Related]
18. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters.
Gélinas C; Temin HM
Oncogene; 1988 Oct; 3(4):349-55. PubMed ID: 2856247
[TBL] [Abstract][Full Text] [Related]
19. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.
Gupta N; Delrow J; Drawid A; Sengupta AM; Fan G; Gélinas C
Cancer Res; 2008 Feb; 68(3):808-14. PubMed ID: 18245482
[TBL] [Abstract][Full Text] [Related]
20. Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts.
Capobianco AJ; Simmons DL; Gilmore TD
Oncogene; 1990 Mar; 5(3):257-65. PubMed ID: 2179815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
